QIM
REGN icon

Quantitative Investment Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Quantitative Investment Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.33M Buy
+3,014
New +$2.31M 0.24% 118
2025
Q3 		– Sell
-678
Closed -$355K – 462
2025
Q2 		$355K Buy
+678
New +$378K 0.05% 236
2025
Q1 		– Sell
-6,898
Closed -$4.91M – 457
2024
Q4 		$4.91M Buy
6,898
+1,686
+32% +$1.41M 0.37% 66
2024
Q3 		$5.48M Buy
5,212
+660
+14% +$734K 0.54% 38
2024
Q2 		$4.78M Sell
4,552
-3,091
-40% -$3M 0.52% 44
2024
Q1 		$7.36M Sell
7,643
-17,552
-70% -$16.7M 0.43% 45
2023
Q4 		$22.1M Buy
25,195
+22,087
+711% +$18.2M 1.27% 14
2023
Q3 		$2.56M Buy
+3,108
New +$2.44M 0.39% 59
2023
Q2 		– Sell
-14,556
Closed -$12M – 347
2023
Q1 		$12M Buy
+14,556
New +$11M 2.52% 7
2022
Q2 		– Sell
-23,747
Closed -$16.6M – 293
2022
Q1 		$16.6M Buy
23,747
+16,540
+229% +$10.5M 1.79% 7
2021
Q4 		$4.55M Sell
7,207
-7,980
-53% -$4.91M 0.64% 42
2021
Q3 		$9.19M Buy
15,187
+11,175
+279% +$6.94M 0.83% 27
2021
Q2 		$2.24M Buy
+4,012
New +$2.03M 0.2% 117
2020
Q1 		– Sell
-17,572
Closed -$6.6M – 769
2019
Q4 		$6.6M Buy
+17,572
New +$5.91M 0.2% 129
2019
Q2 		– Sell
-500
Closed -$205K – 794
2019
Q1 		$205K Sell
500
-2,200
-81% -$906K 0.01% 602
2018
Q4 		$1.01M Buy
2,700
+200
+8% +$73.2K 0.05% 284
2018
Q3 		$1.01M Buy
+2,500
New +$951K 0.04% 300
2017
Q3 		– Sell
-91,600
Closed -$45M – 812
2017
Q2 		$45M Buy
+91,600
New +$40.1M 0.68% 18
2016
Q2 		– Sell
-3,500
Closed -$1.26M – 891
2016
Q1 		$1.26M Buy
+3,500
New +$1.44M 0.06% 357
2015
Q2 		– Sell
-5,900
Closed -$2.66M – 647
2015
Q1 		$2.66M Buy
5,900
+2,200
+59% +$932K 0.26% 76
2014
Q4 		$1.52M Buy
+3,700
New +$1.46M 0.23% 95
2013
Q4 		– Sell
-9,200
Closed -$2.88M – 693
2013
Q3 		$2.88M Buy
+9,200
New +$2.42M 0.26% 76

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Quantitative Investment Management's REGN Position: Q1 2026 in Review

Quantitative Investment Management opened a new position in Regeneron Pharmaceuticals (REGN) in Q1 2026: 3,014 shares worth $2.33M. The stake represents 0.24% of the portfolio and ranks #118 among its holdings. This is a return to the name: Quantitative Investment Management previously reported a position in REGN as recently as Q2 2025.

Quantitative Investment Management first reported a position in REGN in Q3 2013 and has held it in 22 quarters since. The position peaked at $45M in Q2 2017. 1,393 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Quantitative Investment Management held 3,014 shares of Regeneron Pharmaceuticals worth $2.33M as of Q1 2026.
  • Regeneron Pharmaceuticals was a new Quantitative Investment Management position in Q1 2026.
  • Regeneron Pharmaceuticals made up 0.24% of Quantitative Investment Management's portfolio in Q1 2026, its #118 holding.
  • Quantitative Investment Management first reported a position in Regeneron Pharmaceuticals in Q3 2013 and has held it in 22 quarters since.
  • Quantitative Investment Management's Regeneron Pharmaceuticals position peaked at $45M in Q2 2017.
  • 1,393 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Quantitative Investment Management's 13F filing for Q1 2026, filed 15 May 2026.